FDA Clearance Tracker · P030050-S028
SCULPTRA Aesthetic (injectable poly-L Lactic acid)
Last checked: Nov 20, 2026Latest source record: May 1, 2018 (this decision)Source: openFDAMethods & limitations
Decided
May 1, 2018
Approved
Time to decision
147 days
Received Dec 5, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P030050-S028
- Device name
- SCULPTRA Aesthetic (injectable poly-L Lactic acid)
- Applicant
- Q-Med AB
- Applicant location
- Uppsala
- Received
- Dec 5, 2017
- Decided
- May 1, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol - OSB
- Original approval
- P030050
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the post-approval study (PAS) protocol.
Source documents
Other decisions for Q-Med AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Restylane® ContourPMA supplement
P140029-S054 · Decided Mar 20, 2026 · 239 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.